Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept dose-ranging trial in neovascular age-related macular degeneration
2017-004826-14Phase 3Unknown
- Sponsor
- Chengdu Kanghong Biotechnology Co., Ltd.
- Start
- Sep 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of conbercept in exudative macular degeneration (3 arms), sponsored by Chengdu Kanghong Biotechnology Co., Ltd. Primary endpoint: Change from baseline in best corrected visual acuity at Week 36. Status: unknown.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2017-004826-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004826-14.